PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.

ABSTRACT:

Background

Basal-like breast cancers (BLBCs) are a leading cause of cancer death due to their capacity to metastasize and lack of effective therapies. More than half of BLBCs have a dysfunctional BRCA1. Although most BRCA1-deficient cancers respond to DNA-damaging agents, resistance and tumor recurrence remain a challenge to survival outcomes for BLBC patients. Additional therapies targeting the pathways aberrantly activated by BRCA1 deficiency are urgently needed.

Methods

Most BRCA1-deficient BLBCs carry a dysfunctional INK4-RB pathway. Thus, we created genetically engineered mice with Brca1 loss and deletion of p16^INK4A, or separately p18^INK4C, to model the deficient INK4-RB signaling in human BLBC. By using these mutant mice and human BRCA1-deficient

SUBMITTER: Bai F 

PROVIDER: S-EPMC7819225 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature